In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
Press Release|Articles|October 11, 2023
Phastar Net-Zero Target Approved by the Science Based Targets Initiative
Advertisement
Phastar has had its net-zero target approved by the Science Based Targets initiative (SBTi). The SBTi is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science and is considered the gold standard for net-zero.
A component of Phastar’s commitment to SBTi is the pledge to achieve the Science Based Targets initiative (SBTi) Net-Zero Standard by 2035. By adopting stringent sustainability standards, Phastar aims to reduce its carbon footprint, engage with stakeholders, and promote responsible business practices.
In a press release, Phastar Chief Executive Officer Graham Clark said: “Having our net-zero target approved by the SBTi underscores our commitment to corporate responsibility and sustainable business practices. As a company, we pride ourselves on our mission to make a meaningful difference in the world, and on being a great company to work with and work for."
Phastar has already taken steps to hit net zero by 2035. Measures taken so far include strengthening the company’s emissions-measurement processes to enable more easy tracking. The organization has also developed and launched a sustainability strategy to outline exactly how it will reduce its emissions, as well as help its suppliers to do the same. Phastar also plans to roll out policies, initiatives, and incentives throughout its global team to help it become a more environmentally friendly business.
Clark continued, “Our net-zero by 2035 target is well ahead of industry norms and demonstrates Phastar’s dedication to reducing our carbon emissions. No one organization can tackle climate change alone, meaning we all must work together if we are to succeed. During our work so far, we have been extremely encouraged to find that many of our partners and clients already share our business values in this regard. We believe this will, ultimately, drive faster change."
Reference
Phastar Net-Zero Target Approved by the Science Based Targets Initiative. (2023, October 4). Phastar.
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5